39P Determination of essential biomarkers in lung cancer: a real-world data study in Spain.<\/p>\n
V. Calvo de Juan<\/u>1<\/sup>, M. Cobo Dols2<\/sup>, D. Rodriguez-Abreu3<\/sup>, E. Carcereny4<\/sup>, A. Cantero5<\/sup>, R. Bernab\u00e9 Caro6<\/sup>, G. Benitez Lopez3<\/sup>, R. Lopez Castro7<\/sup>, B. Massuti Sureda8<\/sup>, E. del Barco9<\/sup>, M.R. Garcia Campelo10<\/sup>, M. Guirado11<\/sup>, C.J.C. Camps Herrero12<\/sup>, A.L.O. Ortega Granados13<\/sup>, J.L. Gonzalez-Larriba14<\/sup>, A. Sanchez Hernandez15<\/sup>, C. Gonzalez Ojea16<\/sup>, M.A. Sala Gonzalez17<\/sup>, O.J. Juan Vidal18<\/sup>, M. Provencio Pulla1<\/sup> [Text Wrapping Break]1<\/sup>Medical Oncology Department, University Hospital Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain, 2<\/sup>Medical Oncology, Biomedical Research Institute of M\u00e1laga (IBIMA), Malaga, Spain, 3<\/sup>Complejo Hospitalario Universitario Insular-Materno Infantil, Las Palmas De Gran Canaria, Spain, 4<\/sup>National and Kapodistrian University & Frontier Science Foundation Hellas, Athens, Greece, 5<\/sup>Oncolog\u00eda M\u00e9dica., Hospital Regional Universitario M\u00e1laga Carlos Haya, Malaga, Spain, 6<\/sup>Medical Oncology, Hospital Universitario Virgen del Rocio, Sevilla, Spain, 7<\/sup>Radiation And Medical Oncology Department, Hospital Clinico Universitario De Valladolid, Valladolid, Spain, 8<\/sup>Medical Oncology department, Hospital General Universitario de Alicante, Alicante, Spain, 9<\/sup>ONcology, HOSP. CLINICO UNIVERSITARIO SALAMANCA, Salamanca, Spain, 10<\/sup>Dept. Medical Oncology, Instituto de Investigaci\u00f3n Biom\u00e9dica de A Coru\u00f1a (INIBIC), A Coru\u00f1a, Spain, 11<\/sup>Hospital General Universitario de Elche, Elche, Alicante, Spain, 12<\/sup>Hospital General Universitario Valencia, Valencia, Spain, 13<\/sup>Medical Oncology Department, Hospital Universitario de Ja\u00e9n, Ja\u00e9n, Jaen, Spain, 14<\/sup>Medical Oncology department, Hospital Clinico Universitario San Carlos, Madrid, Spain, 15<\/sup>Medical Oncology Department, Consorcio Hospitalario Provincial de Castell\u00f3n, Castellon De La Plana, Spain, 16<\/sup>Hospital Universitario Alvaro Cunqueiro, Vigo, Pontevedra, Spain, 17<\/sup>Hospital Universitario de Basurto, Bilbao, Spain, 18<\/sup>Medical Oncology Dept., Hospital Universitari i Polit\u00e8cnic La Fe, Valencia, Spain<\/p>\n Background:<\/strong> The Thoracic Tumours Registry (TTR) is an observational, prospective, registry-based study that included patients diagnosed with lung cancer and other thoracic tumours, from September 2016 to date. This TTR study was sponsored by the Spanish Lung Cancer Group (GECP) Foundation, an independent, scientific, multidisciplinary oncology society that coordinates more than 550 experts and 182 hospitals across the Spanish territory.<\/p>\n Methods:<\/strong> To study the situation of biomarker testing in Spain.<\/p>\n Results:<\/strong> 9,239 patients diagnosed with stage IV non-small cell lung cancer (NSCLC) were analysed. 7,467 (80.8%) were non-squamous and 1,772 (19.2%) were squamous. Tumour marker testing was performed in 85.0% of patients with non-squamous tumours vs 56.3% in those with squamous tumours (p-value <0.001). The global testing of EGFR, ALK, and ROS1 was 78.9%, 64.7%, 35.6% respectively, in non-squamous histology. PDL1 was determined globally in the same period (46.9%), although if we focus on the last 3 years it exceeds 85%. There has been a significant increase in the last few years of all determinations and there are even close to 10% of molecular determinations that do not yet have targeted drug approval but will have it in the near future. 4,115 cases had a positive result (44.5%) for either EGFR, ALK, KRAS, BRAF, ROS1, or PDL1.<\/p>\n Conclusions:<\/strong> Despite the lack of a national project and standard protocol in Spain that regulates the determination of biomarkers, the situation is similar to other European countries. Given the growing number of different determinations and their high positivity, national strategies are urgently needed to implement next-generation sequencing NGS in an integrated and cost-effective way in lung cancer.<\/p>\n Clinical trial identification:<\/strong> NCT02941458<\/p>\n